Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 182 citations
https://doi.org/10.1016/s1470-2045(20)30496-4
X
Xiuwen Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
315
Papers
7.7K
Citations
46
h-index
127
i10-index
Xiuwen Wang is an academic researcher from Second Hospital of Shandong University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 46, co-authored 268 publications.
ORCID: 0000-0001-6494-122XPapers by this author
worksEstrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation
2014 · Molecular Cancer · 141 citations
https://doi.org/10.1186/1476-4598-13-137
The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
2020 · Frontiers in Oncology · 58 citations
https://doi.org/10.3389/fonc.2020.594125
Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1
2015 · Scientific Reports · 53 citations
https://doi.org/10.1038/srep16355
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
2023 · EClinicalMedicine · 48 citations
https://doi.org/10.1016/j.eclinm.2023.101952
Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer
2015 · BMC Cancer · 47 citations
https://doi.org/10.1186/s12885-015-1553-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat